VNDA · Vanda Pharmaceuticals Inc.

Summary

Vanda Pharmaceuticals Inc. filed an 8-K on February 19, 2026, disclosing matters under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements, including a Form of Performance Restricted Stock Unit Award under the Amended and Restated 2016 Equity Incentive Plan as Exhibit 10.1 under Item 9.01.

Key takeaways

• Item 5.02 disclosure on February event involving directors or officers.
• Form of Performance Restricted Stock Unit Award under Amended and Restated 2016 Equity Incentive Plan.
• Exhibit 10.1 referenced in Item 9.01.